Skip to contentF
Filana Therapeutics, Inc.
F
FLNAFilana Therapeutics, Inc. Q4 2014 · 10-K
Revenue—
Net Income-$2.16M-$2.16MN/M vs Q4 2013 EPS Diluted-$0.05-$0.05N/M vs Q4 2013 Operating Incomederived-$2,167,000N/M The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Filana Therapeutics, Inc. · CIK 1069530 · Engraved from SEC EDGAR
Operating Cash Flowderived
Free Cash Flowderived-$2,564,000— ended Dec 31, 2014 · filed Feb 18, 2015 · 49 d after period end